News & Updates

The use of sorafenib as an adjuvant therapy after radiofrequency ablation (RFA) appears to improve survival outcomes in patients with recurrent hepatocellular carcinoma who underwent hepatectomy, according to a study.

Use of pimavanserin appears to be more effective than atypical antipsychotic agents in reducing mortality among Parkinson’s disease patients during the first 180 days of treatment, reveals a study. However, such benefit is seen only in community-dwelling patients and not in nursing home residents.

Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.

Prescription of antipsychotic and anxiolytic medications has decreased among residents with dementia in Veterans Health Administration (VHA) nursing homes, but overall prescribing of other psychotropic and opioid agents has increased, reports a study.

Switching from intravenous to subcutaneous infliximab appears to be safe and well-accepted, resulting in a reduced risk of relapse in some inflammatory bowel disease (IBD) patients, according to data from the REMSWITCH study.

The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.

Patients diagnosed with acute myeloid leukaemia with an FLT3 mutation (FLT3+ AML) may benefit from the addition of an FLT3 inhibitor to intensive chemotherapy postinduction by improving event-free (EFS) or overall survival (OS), suggests a study.